These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

378 related articles for article (PubMed ID: 29859193)

  • 1. FOXP4-AS1 participates in the development and progression of osteosarcoma by downregulating LATS1 via binding to LSD1 and EZH2.
    Yang L; Ge D; Chen X; Qiu J; Yin Z; Zheng S; Jiang C
    Biochem Biophys Res Commun; 2018 Aug; 502(4):493-500. PubMed ID: 29859193
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The carcinogenic complex lncRNA FOXP4-AS1/EZH2/LSD1 accelerates proliferation, migration and invasion of gastric cancer.
    Chen RY; Ju Q; Feng LM; Yuan Q; Zhang L
    Eur Rev Med Pharmacol Sci; 2019 Oct; 23(19):8371-8376. PubMed ID: 31646567
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long noncoding RNA HOXD-AS1 aggravates osteosarcoma carcinogenesis through epigenetically inhibiting p57 via EZH2.
    Gu W; Zhang E; Song L; Tu L; Wang Z; Tian F; Aikenmu K; Chu G; Zhao J
    Biomed Pharmacother; 2018 Oct; 106():890-895. PubMed ID: 30119259
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Knockdown of ZEB2-AS1 inhibits cell proliferation, invasion and induces apoptosis in osteosarcoma by combining with EZH2.
    Zhang B; Fan DB; Liu L; Qin Y; Feng DQ
    Eur Rev Med Pharmacol Sci; 2020 Jun; 24(12):6533-6539. PubMed ID: 32633340
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Upregulated long non-coding RNA AGAP2-AS1 represses LATS2 and KLF2 expression through interacting with EZH2 and LSD1 in non-small-cell lung cancer cells.
    Li W; Sun M; Zang C; Ma P; He J; Zhang M; Huang Z; Ding Y; Shu Y
    Cell Death Dis; 2016 May; 7(5):e2225. PubMed ID: 27195672
    [TBL] [Abstract][Full Text] [Related]  

  • 6. LINC00511 promotes the progression of non-small cell lung cancer through downregulating LATS2 and KLF2 by binding to EZH2 and LSD1.
    Zhu FY; Zhang SR; Wang LH; Wu WD; Zhao H
    Eur Rev Med Pharmacol Sci; 2019 Oct; 23(19):8377-8390. PubMed ID: 31646568
    [TBL] [Abstract][Full Text] [Related]  

  • 7. LINC01116 promotes proliferation, invasion and migration of osteosarcoma cells by silencing p53 and EZH2.
    Zhang ZF; Xu HH; Hu WH; Hu TY; Wang XB
    Eur Rev Med Pharmacol Sci; 2019 Aug; 23(16):6813-6823. PubMed ID: 31486480
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Circ100284 promotes invasion and migration of osteosarcoma cells by down-regulating PTEN and EMP1.
    Liu YD; Liu LP
    Eur Rev Med Pharmacol Sci; 2020 Jun; 24(12):6540-6550. PubMed ID: 32633341
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Silencing of long noncoding RNA SBF2-AS1 inhibits proliferation, migration and invasion and contributes to apoptosis in osteosarcoma cells by upregulating microRNA-30a to suppress FOXA1 expression.
    Dai JH; Huang WZ; Li C; Deng J; Lin SJ; Luo J
    Cell Cycle; 2019 Oct; 18(20):2727-2741. PubMed ID: 31432728
    [No Abstract]   [Full Text] [Related]  

  • 10. Downregulation of long non-coding RNA DBH-AS1 inhibits osteosarcoma progression by PI3K-AKT signaling pathways and indicates good prognosis.
    Liu ZB; Wang JA; Lv RQ
    Eur Rev Med Pharmacol Sci; 2019 Feb; 23(4):1418-1427. PubMed ID: 30840262
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The carcinogenic complex lncRNA DUXAP8/EZH2/LSD1 accelerates the proliferation, migration and invasion of colorectal cancer.
    Gong A; Huang Z; Ge H; Cai Y; Yang C
    J BUON; 2019; 24(5):1830-1836. PubMed ID: 31786844
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ELK1-induced upregulation of long non-coding RNA MIR100HG predicts poor prognosis and promotes the progression of osteosarcoma by epigenetically silencing LATS1 and LATS2.
    Su X; Teng J; Jin G; Li J; Zhao Z; Cao X; Guo Y; Guo M; Li X; Wu J; Wang C; Guo Z; Guo Q
    Biomed Pharmacother; 2019 Jan; 109():788-797. PubMed ID: 30551532
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Downregulated Long Non-Coding RNA MSC-AS1 Inhibits Osteosarcoma Progression and Increases Sensitivity to Cisplatin by Binding to MicroRNA-142.
    Zhang L; Zhao G; Ji S; Yuan Q; Zhou H
    Med Sci Monit; 2020 Mar; 26():e921594. PubMed ID: 32155139
    [TBL] [Abstract][Full Text] [Related]  

  • 14.
    Luo Y; Tao H; Jin L; Xiang W; Guo W
    Cancer Biother Radiopharm; 2020 Feb; 35(1):58-65. PubMed ID: 31724892
    [No Abstract]   [Full Text] [Related]  

  • 15. Upregulation of long non-coding RNA NNT-AS1 promotes osteosarcoma progression by inhibiting the tumor suppressive miR-320a.
    Li C; Zhang S; Qiu T; Wang Y; Ricketts DM; Qi C
    Cancer Biol Ther; 2019; 20(4):413-422. PubMed ID: 30489194
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long non-coding RNA AGAP2-AS1 exerts oncogenic properties in glioblastoma by epigenetically silencing TFPI2 through EZH2 and LSD1.
    Luo W; Li X; Song Z; Zhu X; Zhao S
    Aging (Albany NY); 2019 Jun; 11(11):3811-3823. PubMed ID: 31186379
    [TBL] [Abstract][Full Text] [Related]  

  • 17. LncRNA AFAP1-AS1 promotes tumorigenesis and epithelial-mesenchymal transition of osteosarcoma through RhoC/ROCK1/p38MAPK/Twist1 signaling pathway.
    Shi D; Wu F; Mu S; Hu B; Zhong B; Gao F; Qing X; Liu J; Zhang Z; Shao Z
    J Exp Clin Cancer Res; 2019 Aug; 38(1):375. PubMed ID: 31443665
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long non-coding RNA FOXP4-AS1 facilitates the biological functions of hepatocellular carcinoma cells via downregulating ZC3H12D by mediating H3K27me3 through recruitment of EZH2.
    Ye J; Fu Y; Wang Z; Yu J
    Cell Biol Toxicol; 2022 Dec; 38(6):1047-1062. PubMed ID: 34545456
    [TBL] [Abstract][Full Text] [Related]  

  • 19. LncRNA RBM5-AS1 Promotes Osteosarcoma Cell Proliferation, Migration, and Invasion.
    Deng B; Pan R; Ou X; Wang T; Wang W; Nie Y; Chen H
    Biomed Res Int; 2021; 2021():5271291. PubMed ID: 33816613
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HIF-1α induced long noncoding RNA FOXD2-AS1 promotes the osteosarcoma through repressing p21.
    Ren Z; Hu Y; Li G; Kang Y; Liu Y; Zhao H
    Biomed Pharmacother; 2019 Sep; 117():109104. PubMed ID: 31228799
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.